Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Galera Therapeutics, Inc. | grtx-ex321_7.htm |
| EX-31.2 - EX-31.2 - Galera Therapeutics, Inc. | grtx-ex312_9.htm |
| EX-31.1 - EX-31.1 - Galera Therapeutics, Inc. | grtx-ex311_8.htm |
| EX-23.1 - EX-23.1 - Galera Therapeutics, Inc. | grtx-ex231_235.htm |
| EX-10.11 - EX-10.11 - Galera Therapeutics, Inc. | grtx-ex1011_370.htm |
| EX-4.2 - EX-4.2 - Galera Therapeutics, Inc. | grtx-ex42_236.htm |
| 10-K - 10-K - Galera Therapeutics, Inc. | grtx-10k_20191231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Galera Therapeutics, Inc. (the “Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
March 10, 2020 |
/s/ Christopher Degnan |
|
|
Christopher Degnan |
|
|
Chief Financial Officer (principal financial officer) |